Clinical and regulatory implications of active run‐in phases in long‐term studies for bipolar disorder
Authors:
- 30 November 2013
- journal article
- review article
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 129 (5) , 328-342
Abstract
Objective: The integration of new treatments into the market and routine clinical practice should be dependent on robustness of evidence from randomised controlled trials (RCTs). We assessed study designs of long‐term studies for bipolar disorder of all second‐generation antipsychotics (SGAs) submitted to the Food and Drug Administration (FDA) and the completeness of evidence submitted to the regulatory agency.Method: Systematic review of double‐blind RCTs comparing SGAs with placebo or active drugs in adults. FDA website and electronic databases were searched until July 2013.Results: Six placebo‐controlled trials comparing aripiprazole, olanzapine, quetiapine and ziprasidone were found in the FDA website. Electronic searches found four additional RCTs about aripiprazole, olanzapine or quetiapine. All RCTs (either submitted to FDA or not) selected patients who responded to acute treatment to increase the treatment effect observed in the long‐term phase (enrichment design). By contrast, in the prescribing information sheets for all SGAs, the reported indication was ‘maintenance treatment of bipolar disorder’.Conclusion: Extrapolation of results from enrichment studies to the more general population of patients should be carried out cautiously because average treatment benefits are likely to be less in unselected patients. Clear guidance for regulatory submission of RCTs is needed.Keywords
This publication has 26 references indexed in Scilit:
- Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overviewActa Psychiatrica Scandinavica, 2012
- Continuation of Quetiapine Versus Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I DisorderThe Journal of Clinical Psychiatry, 2011
- Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysisThe Lancet, 2011
- Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized studyBipolar Disorders, 2011
- Ziprasidone Plus a Mood Stabilizer in Subjects With Bipolar I DisorderThe Journal of Clinical Psychiatry, 2010
- Maintenance Treatment for Patients With Bipolar I Disorder: Results From a North American Study of Quetiapine in Combination With Lithium or Divalproex (Trial 127)American Journal of Psychiatry, 2009
- Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126)Journal of Affective Disorders, 2008
- Randomized, Placebo-Controlled Trial of Olanzapine as Maintenance Therapy in Patients With Bipolar I Disorder Responding to Acute Treatment With OlanzapineAmerican Journal of Psychiatry, 2006
- Olanzapine Versus Lithium in the Maintenance Treatment of Bipolar Disorder: A 12-Month, Randomized, Double-Blind, Controlled Clinical TrialAmerican Journal of Psychiatry, 2005
- Run-in Periods in Randomized TrialsJAMA, 1998